These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10544850)

  • 1. Long-term prognosis of patients with juvenile dermatomyositis initially treated with intravenous methylprednisolone pulse therapy.
    Huang JL
    Clin Exp Rheumatol; 1999; 17(5):621-4. PubMed ID: 10544850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis.
    Lang B; Dooley J
    J Pediatr; 1996 Mar; 128(3):429-32. PubMed ID: 8774518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical analysis of 11 cases of juvenile dermatomyositis and polymyositis].
    Ito S; Miyamae T; Imagawa T; Katakura S; Mori M; Tomono J; Ibe M; Mituda T; Aihara Y; Yokota S
    Ryumachi; 1998 Dec; 38(6):785-92. PubMed ID: 10047716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulse Dose Methylprednisolone Therapy for Adult Idiopathic Inflammatory Myopathy.
    Raghu P; Manadan AM; Schmukler J; Mathur T; Block JA
    Am J Ther; 2015; 22(4):244-7. PubMed ID: 25490616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of intravenous megadoses of methylprednisolone for treatment of dermatomyositis in children].
    Romicka AM
    Pediatr Pol; 1995 Mar; 70(3):243-8. PubMed ID: 8657493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis.
    Rouster-Stevens KA; Gursahaney A; Ngai KL; Daru JA; Pachman LM
    Arthritis Rheum; 2008 Feb; 59(2):222-6. PubMed ID: 18240180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.
    Huber AM; Lang B; LeBlanc CM; Birdi N; Bolaria RK; Malleson P; MacNeil I; Momy JA; Avery G; Feldman BM
    Arthritis Rheum; 2000 Mar; 43(3):541-9. PubMed ID: 10728746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravenous cyclophosphamide pulse therapy for refractory juvenile dermatomyositis].
    Nakashima S; Mori M; Miyamae T; Ito S; Ibe M; Aihara Y; Yokota S
    Ryumachi; 2002 Dec; 42(6):895-902. PubMed ID: 12632609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
    Lopate G; Pestronk A; Al-Lozi M
    Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis.
    Laxer RM; Stein LD; Petty RE
    Arthritis Rheum; 1987 Mar; 30(3):328-34. PubMed ID: 3566824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate.
    Al-Mayouf S; Al-Mazyed A; Bahabri S
    Clin Rheumatol; 2000; 19(2):138-41. PubMed ID: 10791626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of severe idiopathic orbital inflammation with intravenous methylprednisolone.
    Bijlsma WR; Paridaens D; Kalmann R
    Br J Ophthalmol; 2011 Aug; 95(8):1068-71. PubMed ID: 21349945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medications received by patients with juvenile dermatomyositis.
    Kishi T; Bayat N; Ward MM; Huber AM; Wu L; Mamyrova G; Targoff IN; Warren-Hicks WJ; Miller FW; Rider LG;
    Semin Arthritis Rheum; 2018 Dec; 48(3):513-522. PubMed ID: 29773230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Two children with skin rash and muscle weakness: juvenile dermatomyositis].
    Boogaard R; Drexhage VR; van Suijlekom-Smit LW
    Ned Tijdschr Geneeskd; 2005 Jan; 149(3):146-50. PubMed ID: 15693592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical analysis of 50 children with juvenile dermatomyositis.
    Kishi T; Miyamae T; Hara R; Nakajima S; Imagawa T; Mori M; Yokota S
    Mod Rheumatol; 2013 Mar; 23(2):311-7. PubMed ID: 22526832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the biomarkers related to the clinical course and outcomes of juvenile dermatomyositis.
    Lin TW; Hu YC; Chiang BL
    J Microbiol Immunol Infect; 2023 Apr; 56(2):416-423. PubMed ID: 36572597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features of patients with juvenile and adult dermatomyositis].
    Szalmás O; Nagy-Vince M; Dankó K; Farkas F
    Orv Hetil; 2015 Sep; 156(37):1491-6. PubMed ID: 26552025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
    J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety.
    Riley P; Maillard SM; Wedderburn LR; Woo P; Murray KJ; Pilkington CA
    Rheumatology (Oxford); 2004 Apr; 43(4):491-6. PubMed ID: 14722349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.